Skip to main content
. Author manuscript; available in PMC: 2020 Aug 13.
Published in final edited form as: Lung Cancer. 2018 Aug 20;124:283–290. doi: 10.1016/j.lungcan.2018.08.016

Fig. 2.

Fig. 2.

Dose Response in TRT for ES-SCLC.

A-Survival all thoracic radiotherapy patients < 45 Gy vs. ≥45 Gy.

B-Survival thoracic radiotherapy patients after 12 weeks of chemotherapy < 45 Gy vs. ≥45 Gy.

C-Survival all thoracic radiotherapy patients low vs. intermediate vs. high dose.

D-Survival thoracic radiotherapy patients after 12 weeks of chemotherapy low vs. intermediate vs. high dose.